RxDoctor Payments Data

Lauren Digiovine, MD

Ophthalmology · Morgantown, WVNPI 1285948836

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 30 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Alcon at 45.9% of the total. Reporting peaked in 2024 at $374 and has fallen 67.7% since, to $121 in 2025.

$914in general payments, 2019–2025

Across 30 payments — averaging $30.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$420
  • Bausch & Lomb Americas Inc.$133
  • AbbVie$97
  • Sight Sciences, Inc.$63
  • Mallinckrodt Hospital Products Inc.$44
  • Johnson & Johnson Surgical Vision, Inc.$42
  • plus $116 from 5 others

What the payments were for

  • Food & beverage$914100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$914 in reported general payments places this provider in the 55th percentile of 85 ophthalmology providers in West Virginia.

See all ophthalmology providers in West Virginia

Medicare billing

Part B allowed, 2024
$355,656
Medicare patients
1,041
Services billed
2,784

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine41$60,300
LumiganBimatoprost75$30,127
RocklatanNetarsudil Mesylat/Latanoprost26$15,203
Latanoprost705$7,447
CombiganBrimonidine Tartrate/Timolol27$6,807
Prednisolone Acetate206$6,587
Cyclosporine15$6,388
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol18$3,203
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat150$2,895
Ketorolac Tromethamine166$2,382
Timolol Maleate157$2,001
Ofloxacin153$1,521
Brimonidine Tartrate65$1,372
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha56$652
ErythromycinErythromycin Base34$306

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$97$97,234143 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 85 ophthalmology providers in West Virginia.

Other ophthalmology in Morgantown

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →